Pharmacology - 07:31
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Health - Oct 11
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
Pharmacology - Oct 10
Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
wire - news in brief
Category
Results 151 - 200 of 357.
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?
Prestigious grants from the USA go to two Bernese researchers: the biomedical scientists Marianna Kruithof-de Julio and Robert Rieben were the only researchers in Switzerland to receive a grant under
13 substances were detected for the first time in groundwater, 15 were found in concentrations above 100 ng/L. This is the threshold value for pesticides under the Water Protection Ordinance. The researchers are particularly targeting metabolites of chlorothalonil, a product used against fungal attack in cereal, vegetable, wine and ornamental plant cultivation.
Over the next three years, researchers from the Vrije Universiteit Brussel, University of Cambridge, École Supérieure de Physique et de Chimie Industrielles de la ville de Paris (ESPCI-Paris) and Empa will be working together with the Dutch Polymer manufacturer SupraPolix on the next generation of robots: (soft) robots that 'feel pain' and heal themselves.
Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.
The supervision of doctoral students has long been the subject of intense debate both within and beyond the walls of our university.
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc.
(Summer Series): Mathieu Clavel, a master's student in the College of Humanities (CDH) Digital Humanities Institute, is bringing musical heritage from Afghanistan to life using tools from data science and virtual reality.
The ETH Zurich Zentrum and Hönggerberg campuses are not just the study and office spaces of the 30,000 members of ETH: they are also home to a variety of animals and plants.
Novartis receives positive CHMP opinion for Lucentis treatment
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
Empa and the Korean Institute of Civil Engineering and Building Technology (KICT) are committed to working together for a sustainable and networked society.
At yesterday's Hyperloop Competition in Los Angeles, the Swissloop pod achieved a top speed of 252 km/h.
Using similar propulsion technology, the Hyperloop pods developed by EPFL and ETH Zurich turned in a solid performance in Los Angeles: EPFLoop topped out at 238 km/h in the airless tube set up by SpaceX, while Swissloop peaked at 259km/h.
DNA has become the icon of modern bioscience but few people realize that it was Friedrich Miescher, who - almost a century before Watson and Crick - laid the chemical groundwork for the molecular breakthroughs that followed. Today, 150 years after Miescher's first ‘discovery' of DNA, we want to highlight his remarkable work.
The finals of the SpaceX Hyperloop Pod Competition will take place this Sunday. The crowning race will play out in an airless tube, and EPFL's student team is among the top three contenders.
EPFL startup develops innovative method for recycling PET
DePoly, a startup based at EPFL's Valais-Wallis campus, has developed a chemical-based method for recycling PET containers.
DePoly, a startup based at EPFL's Valais-Wallis campus, has developed a chemical-based method for recycling PET containers.
Evaluating the risks posed by synthetic biology
Last week, nearly 70 experts from around the world gathered at EPFL for a workshop on potential threats arising from synthetic biology.
Last week, nearly 70 experts from around the world gathered at EPFL for a workshop on potential threats arising from synthetic biology.
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
Sustainable means of mobility are becoming ever more popular. In Switzerland, around 15,000 people have registered with the online platform carvelo2go, which hires out electric cargo bikes.
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
Emmanuel Abbé is the new Chair of Mathematical Data Science at EPFL. His work answers fundamental questions in machine learning and information theory, and in particular on community detection. Sociologists study the patterns of everyday social interactions and relationships by structuring society in a network.
Pharmacology - 07:31
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Health - Oct 11
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
ERC Synergy Grant for research at the interface of viral infection and cellular regulation
Pharmacology - Oct 10
Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis
Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis